恆指午後曾挫逾300點 藥明系急瀉 中升及聯想曾挫11%-13%
受惠中央推「組合拳」救市,恆指過去三連升累飆1,250點或近8.4%後,今天在新經濟股主導下反覆回落,繼半日收失守20天線後,接近2時沽盤湧現,拖累恆指曾挫323點或2%至15,888,現報15,995,回吐216點或1.3%,總成交額987億元。此外,過去三天累升近9.1%的恆生科指午後曾急吐4.1%低見3,175,現報3,198,回吐3.4%。
藍籌股普遍下跌。美國國會擬以國安為由禁政府與藥明康德(02359.HK)等生物科技公司訂合約,藥明系午後接近2時股價急瀉,曾觸發市調機制,藥明康德由早段高位80元,掉頭急瀉至52.55元,創近四年低喘定,現報62元,挫20%。藥明生物(02269.HK)股價由早段高位32.25元,掉頭曾暴瀉低見21.65元創約五年低喘定,現報23.4元,挫22%;藥明合聯(02268.HK)也曾由早段高位32元,掉頭跌至31.5元,現報25元,挫21%。
阿里健康(00241.HK)、京東健康(06618.HK)、中生(01177.HK)及翰森(03692.HK)跌逾2%-3%,後者股價曾挫8.3%至11.42元。
遭多間外資行削價的中升(00881.HK)重失10天線,曾挫11%低見13.62元,現報13.92元,挫8.5%。特斯拉(TSLA.US)警告今年銷售將大幅放緩,理想(02015.HK)及比亞迪(01211.HK)續跌4%左右。
據報聯想(00992.HK)被美國觀點文章針對,建議美國政府禁用公司電腦,拖累該股今早跌破三條平均線,曾急挫13%低見8.91元,現報9.25元,回吐9.8%。舜宇(02382.HK)重失10天線,午後曾挫7.5%低見55.55元,現報56.85元,回吐5.3%。
再有遊戲獲批的騰訊(00700.HK)仍跌逾2%。其他重磅科網股方面,百度(09888.HK)、美團(03690.HK)及阿里(09988.HK)跌約3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.